



Program - 5th Pituitary Congress
Sunday June 28, 1998 - Tuesday June 30, 1998

- Session 1: Plenary Session**
Moderators: Giovanni Faglia and Steven Lamberts
- 4:15 - 5:00 PM Development of the pituitary
Kathy Mahon
- 5:00 - 5:45 Neuroendocrinological actions and implications of leptin
Felipe Casanueva
- 6:00 - 9:00 Poster session and Reception
- MONDAY**
- Session 2: New insight into pituitary disease provided by genetic disruption**
Moderators: Hiroshi Demura and Larry Jameson
- 8:00 - 8:30 AM Pit 1 and prop 1 phenotypes - clinical aspects
R. Pfaffle
- 8:30 - 9:00 Dopamine D2 Receptor knockout mice
Malcolm Low
- 9:00 - 9:30 Transgenic models to elucidate the roles of inhibin and activin in reproduction, oncogenesis and development.
Martin Matzuk
- 10:00 - 10:30 *Coffee Break*
- Session 3: Advances in Prolactinomas**
Moderators: Gaetano Lombardi and Peter Snyder
- 10:30 - 11:00 AM New therapies of prolactinomas
Jonathan Webster
- 11:00 - 11:30 Recurrent and resistant prolactinomas
Mary Lee Vance
- 11:30 - 12:00 Pregnancy and prolactinomas
Mark Molitch
- 12:00 - 2:00 **Luncheon Seminars**
- Session 4: Genetics of Pituitary Tumors**
Moderators: Julian Davis and Ana Spada
- 2:00 - 2:30 Molecular mechanisms of pituitary oncogenesis: an overview

PM Shlomo Melmed

2:30 - 3:00 Menin: the story unfolds
Allen Spiegel

3:00 - 3:30 Methylation mechanisms in pituitary tumorigenesis
William Farrell, Ph.D.

3:30 - 4:00 *Coffee Break*

Session 5: The growth hormone neuroendocrine axis - new developments
Moderators: Gloria S Tannenbaum and Michael Thorner

4:00 - 4:30 Hypothalamic networks involved in the control of GH secretion
PM Iain CAF Robinson

4:30 - 5:00 Somatostatin receptor subtypes: functions and regulation
Agnes Schonbrunn

5:00 - 5:30 Growth hormone releasing peptides
Roy Smith

5:30 - 6:00 Pituitary Society Business Meeting & Awards
Presentation by (get name from Mary Lee and David)

6:00 - 6:30 Presidential Address (get name from Mary Lee)

Evening free

TUESDAY

Session 6: Plenary Session
Moderators: Iain Clarke and Patricia Hinkle

7:45 - 8:30 Mechanistic and functional insights derived from pituitary cell
AM strains in culture
Armen H. Tashjian Jr.

Session 7: Novel actions of pituitary hormones
Moderators: Charles Clevenger and Karin Eidne

8:30 - 9:00 Actions of the growth hormone/prolactin family of proteins in the
AM placenta
Daniel Linzer

9:00 - 9:30 Growth hormone and IGF effects on bone
Anne Klibanski

9:30 - 10:00 Effect of pituitary hormones on mammary tissue
David Kleinberg

10:00 - 10:30 *Coffee Break*

Session 8: Hot Topics
Moderators: Robert Gagel and Agnes Schonbrunn

10:30 - 10:45 Different retinoid compounds suppress TSHbeta promoter activity
AM in vitro and the thyrotrope-restricted isoform RXR γ 1 appears to mediate this effect
Bryan Haugen

- 10:45 - 11:00 Pituitary-Thyroid axis alterations during use of an RXR-selective retinoid analog
Steven I. Sherman
- 11:00 - 11:15 Identification and functional characterization of an intermediate isoform of the human prolactin receptor
Charles V. Clevenger
- 11:15 - 11:30 A pituitary adenoma in a family with a mutant calcium-sensing receptor. A role of this mutant receptor in pituitary oncogenesis?
Ana O. Hoff
- 11:30 - 11:45 Targeted ablation of gonadotrophs in transgenic mice affects early development of lactotrophs
Hugo Vankelecom, University of Leuven, Belgium
- 11:45 - 12:00 POMC and Somatostatin knockout mice: clinically relevant phenotypes
Ute Hochgeschwender
- 12:00 - 12:15 Progesterone binds to the oxytocin receptor and inhibits receptor signalling: A novel non-genomic steroid action
Hans H. Zingg
- 12:15 - 12:30 A Phase I study of a novel vasopressin receptor antagonist, VPA-985, a potential therapeutic agent for vasopressin-mediated hyponatremia
Gayle P. Orczyk
- 12:30 - 2:30 **Luncheon Seminars**
- Session 9: Pituitary development and regulation**
Moderators: Keith Friend and Stafford Lightman
- 2:30 - 3:00 PM Pituitary specific estrogen receptors
Margaret A. Shupnik
- 3:00 - 3:30 Paracrine interactions in pituitary cell function
Gwen Childs
- 3:30 - 4:00 Model Pituitary Cell lines from Transgenic Mice
Nira Ben-Jonathan
- 4:00 - 4:30 *Coffee Break*
- Session 10: Growth Hormone - too little, too much**
Moderators: Jens Christiansen and Ken Ho
- 4:30 - 5:00 PM The evolving field of growth hormone antagonists: Basic Studies
John Kopchick
- 5:00 - 5:30 Pathophysiology of dominant negative growth hormone mutations
Priscilla Dannies
- 5:30 - 6:00 Clinical studies with growth hormone antagonists
David Clemmons
- 6:00 - 6:30 Metabolic basis of adult growth hormone replacement
Jens Otto Jorgensen
- 6:30 **Closing remarks**

7:30

Beach Banquet

Luncheon Seminars (80 min)

All sessions to run concurrently on Monday and Tuesday

1. Management of difficult pituitary cases

Moderator: Ivor Jackson

Panel: Ian McCutcheon David M. Cook
Akira Shimatzu Sylvia Asa
Brooke Swearingen Paolo Beck-Peccoz
Lynette Kaye Nieman

Cases to be presented by panel members

2. Clinical uses of CRH and management of Cushing's Syndrome

Moderator: James Findling

Speakers: George Chrousos
Beverly Biller
Xavier Bertagna

3. Uses of pituitary irradiation in management of pituitary tumors

Moderator: Kalmon Post

Edward Laws Gamma knife
Jay Loeffler Fractionated conformal radiotherapy
Ariel Barkan Conventional radiation in the treatment of acromegaly

4. Somatostatin and growth hormone releasing peptides: clinical uses

Moderator: Michael Sheppard

Steven Somatostatin receptor mediated radio and
Lamberts chemotherapy
Phillipe Jaquet Lanreotide vs. Sandostatin LAR
Ezio Ghigo Growth hormone releasing peptides

5. Genetic testing

Moderator: Maria Louisa Brandi

Ashley Grossman The clinical use of genetic information in the
management of pituitary tumors and other endocrine
tumor syndromes
Sunita K. Dideoxy fingerprinting for detection of mutations in
Agarwal the MEN1 gene
Mark Hughes Single cell diagnostics

6. New molecular strategies

Moderator: Nancy Cooke

Rob Burgess Novel knockout strategies for mouse mutagenesis
Pamela Mellon Targeted Oncogenesis in Transgenic Mice
William Chin Strategies for the identification of new trans-acting
factors

7. Longterm complications of GH treatment

Moderator: Richard Robbins

Panel:

Charles Sklar

Steve Shalet

Oncological risk in children and adults treated
with growth hormone

Bengt-Ake Bengtsson

8. Novel or controversial therapeutic uses of GH

Moderator: Marcello Delano Bronstein

G. Michael Besser

Growth Hormone Replacement in Adults

David N. Herndon

Treatment of burn patients

Vivien Herman-

GH impact on cardiovascular function

Bonert